ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO180

Fibroblast Growth Factor 23 (FGF23) and Cystic Liver Disease in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Jovanovich, Anna Jeanette, Denver VA / University of Colorado, Denver, Colorado, United States
  • You, Zhiying, UC Denver, Aurora, Colorado, United States
  • Gitomer, Berenice Y., Div. Renal Diseases and Hypertension,, Aurora, Colorado, United States
  • Wolf, Myles, Duke University, Durham, North Carolina, United States
  • Salusky, Isidro B., Mattel Children's Hospital, Los Angeles, California, United States
  • Chonchol, Michel, University of Colorado, Aurora, Colorado, United States
  • Nowak, Kristen L., University of Colorado Denver: Anschutz Medical Campus, Aurora, Colorado, United States

Previous studies have demonstrated that the cystic liver from ADPKD patients markedly expresses FGF23 mRNA and protein. Epidemiological studies have reported an elevation in circulating FGF23 levels in adult ADPKD patients compared to non-ADPKD patients with similar kidney function. We hypothesize that elevated serum iFGF23 levels are associated with greater increases in cystic liver volume in early ADPKD.


440 participants with early ADPKD and normal kidney function (mean eGFR 92± 18mL/min/1.73m2) who participated in HALT Study A were included in this analysis. The cross-sectional and longitudinal (5-year) association of iFGF23 with liver volume, measured as baseline total liver volume and change in total liver volume by magnetic resonance imaging, respectively, were evaluated using linear regression models. iFGF23 levels were measured using stored serum samples obtained at baseline


Participants had a mean (SD) age of 37 ± 8 years. Mean (SD) serum phosphate level and the median (IQR) iFGF23 level were 3.4 ± 0.5 mg/dL and 43 (33–56) pg/mL, respectively. The median (IQR) baseline liver volume was 1790 (1572-2088)ml. After adjustment for age, sex, body mass index, randomization group, systolic blood pressure, estimated glomerular filtration rate, urinary albumin excretion, serum calcium, phosphate, parathyroid hormone level and PKD genotype, higher circulating iFGF23 levels were not associated with liver volume at baseline (ß=35.39, [95% CI -86.75 to 157.53; p=0.60] per doubling in iFGF23). Similarly, higher circulating iFGF23 was not associated with greater percentage increase in liver volume (ß=-1.94, [95% CI -17.04 to 13.15; p=0.80])per doubling in iFGF23.


Our results indicate that circulating iFGF23 is not independently associated with liver volume in ADPKD patients. FGF23 does not appear to represent a valid therapeutic target or a pertinent biomarker for liver cysts progression in patents with early ADPKD.


  • NIDDK Support